Alpha Cognition Inc. Comm... (ACOG)
5.50
0.17 (3.19%)
At close: Mar 25, 2025, 3:59 PM
3.19% (1D)
| Bid | 5.25 |
| Market Cap | 85.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.03 |
| PE Ratio (ttm) | -1.82 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.57 |
| Volume | 78,679 |
| Avg. Volume (20D) | 84,847 |
| Open | 5.29 |
| Previous Close | 5.33 |
| Day's Range | 5.29 - 5.54 |
| 52-Week Range | 4.66 - 7.00 |
| Beta | 2.51 |
About ACOG
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treat...
Industry Financial - Conglomerates
Sector Financial Services
IPO Date n/a
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ACOG
Website https://www.alphacognition.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ACOG stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 263.64% from the latest price.
Stock Forecasts2 months ago
+0%
Alpha Cognition shares are trading higher after th...
Unlock content with
Pro Subscription
